Sociedad Americana de Hirudoterapia

Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery - a literature review

Review published in Handchirurgie Mikrochirurgie Plastische Chirurgie (2007)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyEnsayos clínicosKnobloch K, Gohritz A, Busch K, Spies M, Vogt PM · Handchirurgie, Mikrochirurgie, plastische Chirurgie, 2007

Abstract

Medical leech therapy has enjoyed a renaissance in the world of reconstructive microsurgery during recent years. Especially venous congestion is decreased using hirudo medicinalis application such as following replantation of amputated fingers or congested flaps. They provide a temporary relief to venous engorgement whilst venous drainage is re-established. Living in symbiosis with Aeromonas hydrophila, who can digest the sixfold blood meal related to their body weight, and a broad number of anticoagulant agents such as the thrombin inhibitor hirudin, apyrase as well as collagenase, hyaluronidase, Factor Xa inhibitor and fibrinase I and II, leeches decrease venous congestion. Laser Doppler flowmetry could demonstrate a significant increase in superficial skin perfusion following leech application 16 mm around the biting zone. Following the initial blood meal accounting for about 2.5 ml, the anticoagulant effect of the various leeches enzymes follows within the next 5-6 hours, which both account for the beneficial effects. Infection associated with leech therapy is a documented complication of leech application, with reported incidences ranging from 2.4 to 20 % and a chinolone antibiotic is currently recommended to face the potential Aeromonas hydrophila infection. Anemia is a second adverse effect during medicinal leech application which has to be taken account with repetitive blood samples. Besides the successful applications of leeches in various applications in plastic and reconstructive microsurgery, randomized-controlled trials are pending to elucidate the value of hirudo medicinalis according to evidence-based criteria above from case series and case studies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyEnglish AbstractJournal ArticleReview
Indexed MeSH termsAdolescentAeromonas hydrophilaAnimalsAnti-Bacterial AgentsBlood CoagulationChild, PreschoolClinical Trials as TopicCohort StudiesFemaleFingersGram-Negative Bacterial InfectionsHirudin Therapy

Resumen

Literature review of Hirudo medicinalis applications in microsurgery covering hirudin's mechanism, laser Doppler confirmation of significant superficial skin perfusion increase 16 mm around the bite, infection complications (2.4-20%), and anemia management.

Por qué esto importa para la hirudoterapia

This review examines the clinical use of Hirudo medicinalis in plastic and reconstructive microsurgery, particularly for treating venous congestion following finger replantation or in congested flaps. The abstract details the anticoagulant arsenal in leech saliva—including hirudin, apyrase, collagenase, hyaluronidase, and Factor Xa inhibitors—and reports that laser Doppler flowmetry shows increased skin perfusion 16 mm around the bite zone. This is directly relevant to ASH's domain as a comprehensive overview of hirudotherapy mechanisms, benefits, and complications. Caveats: the authors explicitly note that randomized-controlled trials remain pending, with current evidence drawn from case series and case studies. Reported Aeromonas infection rates range from 2.4–20%, and quinolone prophylaxis is recommended.

Citación

Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery - a literature review.

Knobloch K, Gohritz A, Busch K, Spies M, Vogt PM · Handchirurgie, Mikrochirurgie, plastische Chirurgie, 2007

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.